Register to the Webinar :
New Orphan Regulations

Navigating Orphan Drug Regulations in the US and EU

Orphan drug designation offers real advantages, but only if you understand how the rules actually work in practice.
Exclusivity windows, incentive stacking, regulatory divergence between the FDA and EMA: the details matter, and the timing matters more.

Join AzurBio’s regulatory experts for a deep dive into what biotech companies pursuing their first product need to know before entering the European market.

What is covered:

• How orphan designation criteria differ between the US and EU, and where they overlap.
• Exclusivity periods, incentives, and how to leverage them strategically.
• Common operational risks and how to anticipate them.
• Portfolio-level implications for early-stage biotechs.